Literature DB >> 31934557

Performance of ATA Risk Stratification Systems, Response to Therapy, and Outcome in an Indian Cohort of Differentiated Thyroid Carcinoma Patients: A Retrospective Study.

Rony Ruben1, Praveen V Pavithran1, V Usha Menon1, Vasantha Nair1, Harish Kumar1.   

Abstract

INTRODUCTION: For better individualized management of differentiated thyroid carcinoma (DTC), ATA risk stratification systems (RSS) of 2009 and 2015 as well as a response to therapy re-classification (ATA RTR-2015) are used worldwide for assessing risk of recurrence. But there are no validation studies of these systems from the Indian subcontinent.
OBJECTIVES: To compare ATA RSS-2009, ATA RSS-2015, and ATA RTR-2015 for their accuracy in predicting outcome in DTC patients.
METHODS: This was a retrospective review of 236 adult patients with DTC >1 cm attending the Thyroid Cancer Clinic at our Institute who had undergone total thyroidectomy and radioactive iodine ablation. Initial risk stratification using ATA RSS-2009 and RSS-2015, clinical response at 1 year and outcome at last follow-up measured by clinical end points were collected and analyzed.
RESULTS: ATA RSS-2015 could not be applied to this cohort due to lack of histopathology details. While 77.3% of low-risk ATA RSS-2009 had disease-free status (NED, no evidence of disease) on follow-up, 96.1% of patients, in excellent response in ATA RTR-2015, showed NED. Whereas persistent structural disease was predicted by the high-risk group in ATA RSS-2009 (61.9%) and by the incomplete structural response group in ATA RTR-2015 (57.1%) equally well, the best predictor for NED at 1 year in this cohort was ATA RTR-2015 (p < 0.001).
CONCLUSION: This study found that both ATA RSS-2009 and ATA RTR-2015 are reliable in predicting outcome in DTC patients after initial treatment. However, the response to initial therapy at 1 year predicted outcome more accurately than the initial risk status.
Copyright © 2019 by S. Karger AG, Basel.

Entities:  

Keywords:  ATA risk stratification systems; Differentiated thyroid carcinoma; Indian population; Kerala; Outcome; Validation

Year:  2019        PMID: 31934557      PMCID: PMC6944917          DOI: 10.1159/000500773

Source DB:  PubMed          Journal:  Eur Thyroid J        ISSN: 2235-0640


  13 in total

1.  Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system.

Authors:  R Michael Tuttle; Hernan Tala; Jatin Shah; Rebecca Leboeuf; Ronald Ghossein; Mithat Gonen; Matvey Brokhin; Gal Omry; James A Fagin; Ashok Shaha
Journal:  Thyroid       Date:  2010-10-29       Impact factor: 6.568

2.  Clinical risk factors associated with cervical lymph node recurrence in papillary thyroid carcinoma.

Authors:  Seung-Kuk Baek; Kwang-Yoon Jung; Sun-Mook Kang; Soon-Young Kwon; Jeong-Soo Woo; Seung-Hyun Cho; Eun-Jae Chung
Journal:  Thyroid       Date:  2010-02       Impact factor: 6.568

3.  Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer.

Authors:  David S Cooper; Gerard M Doherty; Bryan R Haugen; Bryan R Hauger; Richard T Kloos; Stephanie L Lee; Susan J Mandel; Ernest L Mazzaferri; Bryan McIver; Furio Pacini; Martin Schlumberger; Steven I Sherman; David L Steward; R Michael Tuttle
Journal:  Thyroid       Date:  2009-11       Impact factor: 6.568

4.  Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patients.

Authors:  Maria Grazia Castagna; Fabio Maino; Claudia Cipri; Valentina Belardini; Alexandra Theodoropoulou; Gabriele Cevenini; Furio Pacini
Journal:  Eur J Endocrinol       Date:  2011-07-12       Impact factor: 6.664

5.  Clinicopathologic Features of Fatal Non-Anaplastic Follicular Cell-Derived Thyroid Carcinomas.

Authors:  Bin Xu; Tihana Ibrahimpasic; Laura Wang; Mona M Sabra; Jocelyn C Migliacci; R Michael Tuttle; Ian Ganly; Ronald Ghossein
Journal:  Thyroid       Date:  2016-09-07       Impact factor: 6.568

6.  Spontaneous remission in thyroid cancer patients after biochemical incomplete response to initial therapy.

Authors:  Fernanda Vaisman; Denise Momesso; Daniel A Bulzico; Cencita H C N Pessoa; Fernando Dias; Rossana Corbo; Mário Vaisman; R Michael Tuttle
Journal:  Clin Endocrinol (Oxf)       Date:  2012-07       Impact factor: 3.478

7.  Treatment guidelines for patients with thyroid nodules and well-differentiated thyroid cancer. American Thyroid Association.

Authors:  P A Singer; D S Cooper; G H Daniels; P W Ladenson; F S Greenspan; E G Levy; L E Braverman; O H Clark; I R McDougall; K V Ain; S G Dorfman
Journal:  Arch Intern Med       Date:  1996-10-28

8.  The clinical and economic burden of a sustained increase in thyroid cancer incidence.

Authors:  Briseis Aschebrook-Kilfoy; Rebecca B Schechter; Ya-Chen Tina Shih; Edwin L Kaplan; Brian C-H Chiu; Peter Angelos; Raymon H Grogan
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-05-15       Impact factor: 4.254

9.  Predictors for papillary thyroid cancer persistence and recurrence: a retrospective analysis with a 10-year follow-up cohort study.

Authors:  Taciana Padilha de Castro; William Waissmann; Taynãna César Simões; Rossana Corbo R de Mello; Denise P Carvalho
Journal:  Clin Endocrinol (Oxf)       Date:  2016-02-23       Impact factor: 3.478

10.  Factors determining the persistence or recurrence of well-differentiated thyroid cancer treated by thyroidectomy and/or radioiodine in the Boston, Massachusetts area: A retrospective chart review.

Authors:  Angela M Leung; Shalini Dave; Stephanie L Lee; Francis X Campion; Jeffrey R Garber; Elizabeth N Pearce
Journal:  Thyroid Res       Date:  2011-04-15
View more
  3 in total

1.  The effect of the area proportion of the metastatic lesion within the central metastatic lymph node on response to therapy in papillary thyroid carcinoma.

Authors:  Liuhong Shi; Liang Zhou; Jianbiao Wang; Lei Jin; Yinjiao Lei; Lian Xia; Lei Xie
Journal:  Oncol Lett       Date:  2021-02-12       Impact factor: 2.967

2.  Clinicopathological features and outcome of thyroglobulin elevation and negative iodine scintigraphy (TENIS) patients with negative neck ultrasound: Experience from a thyroid carcinoma clinic in India.

Authors:  Roopa Vijayan; Shanmuga Sundaram Palaniswamy; Usha Menon Vadayath; Vasantha Nair; Harish Kumar
Journal:  World J Nucl Med       Date:  2021-11-01

3.  Is Male Sex A Prognostic Factor in Papillary Thyroid Cancer?

Authors:  Aleksandra Gajowiec; Anna Chromik; Kinga Furga; Alicja Skuza; Danuta Gąsior-Perczak; Agnieszka Walczyk; Iwona Pałyga; Tomasz Trybek; Estera Mikina; Monika Szymonek; Klaudia Gadawska-Juszczyk; Artur Kuchareczko; Agnieszka Suligowska; Jarosław Jaskulski; Paweł Orłowski; Magdalena Chrapek; Stanisław Góźdź; Aldona Kowalska
Journal:  J Clin Med       Date:  2021-05-31       Impact factor: 4.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.